Smallpox Vaccine

Protein and genome analysis company awarded grant to develop smallpox vaccine

Published in Gene Therapy Weekly, January 20th, 2005

EpiVax, Inc., has been awarded a BioDefense phase I Small Business Innovation Research (SBIR) grant by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. National Institutes of Health (NIH), for developing a genome-derived, epitope-driven smallpox vaccine.

The NIAID/NIH award for $993,771 will be used to screen the genomes of variola (smallpox) and vaccinia (cowpox) for common elements, also known as epitopes that drive protective immunity. However, EpiVax researchers will not be using the actual smallpox virus in conducting their research.

Having successfully proven that EpiVax can accurately identify...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2005-01-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry